JP2002522537A - 改良されたオメプラゾールの方法および組成物 - Google Patents

改良されたオメプラゾールの方法および組成物

Info

Publication number
JP2002522537A
JP2002522537A JP2000564949A JP2000564949A JP2002522537A JP 2002522537 A JP2002522537 A JP 2002522537A JP 2000564949 A JP2000564949 A JP 2000564949A JP 2000564949 A JP2000564949 A JP 2000564949A JP 2002522537 A JP2002522537 A JP 2002522537A
Authority
JP
Japan
Prior art keywords
omeprazole
methoxy
residual
methanol
hydrocarbon solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000564949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002522537A5 (https=
Inventor
アノウシス，ニツク
バンクス，ベンジヤミン・ニユートン
マクマナス，ジエイムズ・ダブリユ
チヨウ，リンウエン
リウ，ホイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22254872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002522537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2002522537A publication Critical patent/JP2002522537A/ja
Publication of JP2002522537A5 publication Critical patent/JP2002522537A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000564949A 1998-08-11 1999-08-06 改良されたオメプラゾールの方法および組成物 Pending JP2002522537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9603798P 1998-08-11 1998-08-11
US60/096.037 1998-08-11
PCT/US1999/017970 WO2000009497A1 (en) 1998-08-11 1999-08-06 Improved omeprazole process and compositions thereof

Publications (2)

Publication Number Publication Date
JP2002522537A true JP2002522537A (ja) 2002-07-23
JP2002522537A5 JP2002522537A5 (https=) 2006-06-15

Family

ID=22254872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000564949A Pending JP2002522537A (ja) 1998-08-11 1999-08-06 改良されたオメプラゾールの方法および組成物

Country Status (18)

Country Link
US (2) US6166213A (https=)
EP (1) EP1104417B1 (https=)
JP (1) JP2002522537A (https=)
KR (1) KR100632725B1 (https=)
CN (1) CN1227246C (https=)
AT (1) ATE360626T1 (https=)
AU (1) AU764642B2 (https=)
BR (1) BR9912883A (https=)
CA (1) CA2338967A1 (https=)
DE (1) DE69935915T2 (https=)
DK (1) DK1104417T3 (https=)
ES (1) ES2285857T3 (https=)
IL (2) IL141324A0 (https=)
NO (1) NO321054B1 (https=)
NZ (1) NZ509798A (https=)
PT (1) PT1104417E (https=)
WO (1) WO2000009497A1 (https=)
ZA (1) ZA200101140B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3457945B2 (ja) 1998-11-10 2003-10-20 アストラゼネカ・アクチエボラーグ オメプラゾールの新規な結晶形

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6303787B1 (en) * 1998-05-27 2001-10-16 Natco Pharma Limited Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
EP1764364A1 (en) * 2002-08-21 2007-03-21 Teva Pharmaceutical Industries Ltd A method for the purification of lansoprazole
US6909004B2 (en) * 2002-08-21 2005-06-21 Teva Pharmaceutical Industries Ltd. Method for the purification of lansoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
PL1802584T3 (pl) * 2004-10-11 2010-03-31 Ranbaxy Laboratories Ltd Sposób wytwarzania podstawionych sulfotlenków
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2007066202A1 (en) * 2005-12-06 2007-06-14 Inogent Laboratories Private Limited Process for the preparation of 2-(2-pyridylmethyl)-sulfinyl-1h-benzimidazoles
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2667682A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN103204841B (zh) * 2013-05-09 2014-06-25 成都天台山制药有限公司 奥美拉唑钠及制备方法
CN104592201A (zh) * 2015-01-13 2015-05-06 江苏中邦制药有限公司 一种奥美拉唑的精制方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN111635393A (zh) * 2020-06-28 2020-09-08 江苏吴中医药集团有限公司 一种艾司奥美拉唑钠的制备方法
CN112679475B (zh) * 2021-01-14 2022-02-15 四川新迪医药化工有限公司 一种奥美拉唑的制备方法及奥美拉唑
WO2023048508A1 (ko) * 2021-09-23 2023-03-30 국립암센터 오메프라졸 갈변물질을 포함하는 암 예방 또는 치료용 약학적 조성물
CN114209697A (zh) * 2021-12-14 2022-03-22 重庆大学附属三峡医院 一种质子泵抑制剂、制备方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5262275A (en) * 1974-05-16 1977-05-23 Haessle Ab Production of organic compound
JPS58192880A (ja) * 1978-04-14 1983-11-10 アクチエボラゲツト・ヘツスレ 新規なベンズイミダゾ−ル化合物
JPH05213936A (ja) * 1991-09-20 1993-08-24 Merck & Co Inc 抗潰瘍剤合成の新規方法
JPH05507699A (ja) * 1990-06-07 1993-11-04 アストラ・アクチエボラーグ オメプラゾールの合成法
WO1997022603A1 (en) * 1995-12-15 1997-06-26 Astra Aktiebolag Method for the synthesis of a benzimidazole compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
GB2239453A (en) * 1989-11-27 1991-07-03 Haessle Ab Omeprazole
ES2026761A6 (es) * 1990-10-31 1992-05-01 Genesis Para La Investigacion Procedimiento de obtencion del omeprazol.
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
SK283805B6 (sk) * 1996-09-09 2004-02-03 Slovakofarma, A. S. Spôsob prípravy omeprazolu
WO1998040378A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose
WO1998040377A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5262275A (en) * 1974-05-16 1977-05-23 Haessle Ab Production of organic compound
JPS58192880A (ja) * 1978-04-14 1983-11-10 アクチエボラゲツト・ヘツスレ 新規なベンズイミダゾ−ル化合物
JPH05507699A (ja) * 1990-06-07 1993-11-04 アストラ・アクチエボラーグ オメプラゾールの合成法
JPH05213936A (ja) * 1991-09-20 1993-08-24 Merck & Co Inc 抗潰瘍剤合成の新規方法
WO1997022603A1 (en) * 1995-12-15 1997-06-26 Astra Aktiebolag Method for the synthesis of a benzimidazole compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009055961, 医薬審第３０７号, 19980330 *
JPN6009055962, 化学実験操作法 上巻, 1963, 第２７版, 第３６５−３９９頁, 株式会社南江堂 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3457945B2 (ja) 1998-11-10 2003-10-20 アストラゼネカ・アクチエボラーグ オメプラゾールの新規な結晶形

Also Published As

Publication number Publication date
IL141324A0 (en) 2002-03-10
KR100632725B1 (ko) 2006-10-16
EP1104417B1 (en) 2007-04-25
PT1104417E (pt) 2007-06-29
WO2000009497A1 (en) 2000-02-24
CN1227246C (zh) 2005-11-16
CA2338967A1 (en) 2000-02-24
DK1104417T3 (da) 2007-07-16
DE69935915T2 (de) 2008-01-10
CN1322201A (zh) 2001-11-14
EP1104417A1 (en) 2001-06-06
NO20010677D0 (no) 2001-02-09
ATE360626T1 (de) 2007-05-15
KR20010072382A (ko) 2001-07-31
EP1104417A4 (en) 2002-12-18
DE69935915D1 (de) 2007-06-06
BR9912883A (pt) 2001-09-25
US6147103A (en) 2000-11-14
IL141324A (en) 2007-05-15
AU764642B2 (en) 2003-08-28
US6166213A (en) 2000-12-26
NZ509798A (en) 2003-06-30
NO20010677L (no) 2001-04-09
NO321054B1 (no) 2006-03-06
ES2285857T3 (es) 2007-11-16
ZA200101140B (en) 2002-04-09
AU5470999A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
JP2002522537A (ja) 改良されたオメプラゾールの方法および組成物
EP2308492B1 (en) Process for preparing lansoprazole
US8614331B2 (en) Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
JP2007161734A (ja) Ｓ−オメプラゾールの新規な形態
JP2003516985A (ja) 改良されたオメプラゾール工程および該化合物の組成物
JP4455815B2 (ja) オメプラゾールのｃ型結晶の製造方法
WO2004020436A1 (en) Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
US6703410B1 (en) Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
WO2005082888A1 (en) Process for the preparation of magnesium salt of omeprazole
EP1626048A1 (en) Crystal of benzimidazole derivative and process for producing the same
HK1034510B (en) Improved omeprazole process and compositions thereof
HK1034510A1 (en) Improved omeprazole process and compositions thereof
MXPA01001542A (en) Improved omeprazole process and compositions thereof
HK1083340A (en) Crystal of benzimidazole derivative and process for producing the same
TW200827357A (en) Improved process for the manufacture of mirtazapine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100330